A new $50 million investment initiative, the Sarat Ventures Y Innovations Biotech Fund, has been launched to support early-stage life sciences companies with strategic ties to Saudi Arabia and the wider MENA region. Anchored by Allocator One, the fund represents a significant step in advancing Saudi Arabia’s Vision 2030 by fostering innovation in knowledge-based industries.
Global Expertise Meets Regional Insight
The fund is co-led by a powerful duo combining global biotech commercialization experience with deep local market knowledge. Dr. Megan Yung of Yung Ventures, part of the Y Innovations Group, brings a strong track record in life sciences development, while Dr. Huda Alfardus, formerly of Saudi Arabia’s first private accelerator Healthgena, provides invaluable regional connections. This leadership team is uniquely positioned to offer portfolio companies seamless entry into the Saudi market and access to the Kingdom’s growing innovation ecosystem.
Unlocking A Multi-Billion Dollar Market
The launch comes as the Saudi biotech sector is projected to reach a value of $11–12 billion by 2030. The fund is designed to catalyze this growth by bridging cutting-edge scientific innovation with strategic partnerships across ministries, research institutions, and healthcare systems in Saudi Arabia.
“Saudi Arabia is uniquely positioned to become a global leader in life sciences,” said Dr. Alfardus. Dr. Yung added, “We are laying the foundation for transformative therapies and sustainable growth… this fund is designed to unlock that potential.”
About Sarat Ventures Y Innovations Biotech Fund
The Sarat Ventures Y Innovations Biotech Fund is a new venture capital initiative focused on early-stage biotech and life sciences companies in the Middle East. It aims to set a new benchmark for biotech investing in the region by combining global commercialization pathways with Saudi Arabia’s strategic infrastructure, positioning MENA as a hub for next-generation therapies and medical innovation.
Source: MEA Tech Watch
